Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (ELAN) has released a groundbreaking report highlighting the widespread issue of canine itchiness in America. The study reveals that 90% of U.S. dogs experience itchiness, with 83% showing increased symptoms during allergy seasons. Pet owners typically wait 6 weeks before seeking veterinary care and spend an average of $173 more during allergy season on treatments. The report emphasizes the emotional and financial toll on pet owners, with 53% feeling judged and 75% feeling hopeless when treatments fail. The study also identifies America's "Itchiest Cities," with Memphis pet owners spending $548 annually on itch treatments compared to the national average of $302. Elanco promotes their new product Zenrelia (ilunocitinib tablets) as a once-daily, cost-effective solution for canine itch relief.

Elanco Animal Health (NYSE: ELAN) has appointed Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen, currently CFO at Hillenbrand, Inc., brings nearly three decades of finance leadership experience, including 15 years at Johnson Controls where he held various executive positions. He succeeds Todd Young, who will remain as an advisor through August 31, 2025.

The company is experiencing strong momentum with seven consecutive quarters of growth and is focusing on accelerating growth, globalizing innovation, expanding margins, and improving cash generation. Elanco also reconfirmed its second quarter and full year guidance issued during the May 7, 2025 earnings call.

Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. CEO Jeff Simmons will attend the BNP Paribas 2nd Annual Animal Health Day on May 22, 2025, at 12:00 p.m. ET. Additionally, both Simmons and CFO Todd Young will participate in a fireside chat at the Stifel 2025 Jaws & Paws Conference on May 29, 2025, at 8:00 a.m. ET.

Both events will feature live audio webcasts accessible through Elanco's investor website under the "Events and Presentations" section, with replays available for a limited time after each event.

Elanco Animal Health (NYSE: ELAN) reported Q1 2025 results with revenue of $1,193 million, showing a 1% decline year-over-year but 4% organic constant currency growth. The company achieved reported net income of $67 million and adjusted net income of $184 million, with reported EPS of $0.13 and adjusted EPS of $0.37. Elanco raised its 2025 revenue guidance to $4,510-$4,580 million, maintaining adjusted EBITDA guidance of $830-$870 million. Key highlights include strong performance in Farm Animal segment, accelerating Pet Health trends, and progress in debt reduction with expected gross debt paydown of $450-$500 million in 2025. The company improved its year-end net leverage ratio target to 3.9x-4.3x, supported by working capital management and a $295 million lotilaner U.S. royalty monetization deal.

Elanco Animal Health (NYSE: ELAN) has announced the sale of royalty and milestone rights for XDEMVY® (lotilaner ophthalmic solution) to Blackstone for $295 million in cash. The deal covers U.S. sales royalties from April 2025 through August 2033. The proceeds will be used to accelerate debt reduction, with Elanco expecting to achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by end-2025. The company will repay portions of outstanding term loans, reducing interest expense by approximately $10 million, offset by the sale of $10 million in royalties. XDEMVY, developed through Elanco's 2019 licensing agreement with Tarsus Pharmaceuticals, is the first FDA-approved medicine for Demodex blepharitis treatment. Elanco retains rights to non-U.S. royalties and future human applications of lotilaner beyond ophthalmic solutions.

Elanco Animal Health (NYSE: ELAN) commemorates the second annual National Parvo Awareness Day, highlighting their breakthrough Canine Parvovirus Monoclonal Antibody (CPMA) treatment. The USDA-conditionally approved CPMA has demonstrated remarkable results with a 93% survival rate for infected puppies, reducing hospital stays by an average of 1.87 days.

Through ParvoTrack, Elanco's pioneering real-time outbreak tracking tool, thousands of cases have been reported nationwide, with Texas, Arizona, Georgia, Florida, Illinois, Indiana, and New York showing the highest outbreak rates. The platform enables pet owners and veterinarians to self-report cases and receive local outbreak alerts.

Elanco has set an ambitious goal to save 1 million puppies from parvovirus by 2030. The company has already saved thousands of puppies in the first year, with success stories including Cookie, Dolly, Patrick, Beatrix, Buster, Luna, and Mono, all of whom made full recoveries after CPMA treatment.

Elanco Animal Health (NYSE: ELAN) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will host a conference call at 8:00 a.m. eastern time to discuss the quarterly performance with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website. Additionally, a replay of the call will be made available on the same platform following the event.

Elanco Animal Health (NYSE: ELAN) announced significant changes to its Board of Directors, reducing the board size to 11 directors by the 2025 Annual Meeting. Three directors - JP Bilbrey, Kathy Turner, and Craig Wallace - will not seek re-election, while William F. Doyle has resigned immediately.

Paul Herendeen will succeed Bilbrey as Chair of the Board's Finance, Strategy and Oversight Committee. The company recently added Dr. Stacey Ma to refresh Board composition.

Additionally, Elanco signed a research agreement with WEDterinary , a newly formed research entity co-founded by Doyle. The partnership will focus on:

• Developing targeted gene therapy treatments for Chronic Kidney Disease (CKD) in cats
• Exploring innovative approaches to increase healthy lifespan in pets
• Utilizing new technologies like gene therapy and AI

The research agreement will be funded within Elanco's existing R&D operating expenses.

Elanco Animal Health (NYSE: ELAN) has entered an agreement with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle. Medgene reports the vaccine has met all USDA platform technology requirements and is in final stages of review for conditional license approval.

The current HPAI outbreak has entered its fourth year, with cross-species transmission affecting nearly 1,000 dairy herds across the U.S. since March 2024. The virus is predicted to persist, making a cattle vaccine critical to slow transmission between birds and cattle.

Jeff Simmons, President and CEO of Elanco, stated the partnership will provide options to fight this disease and believes the product will become part of routine vaccination protocols for U.S. dairy. Mark Luecke, CEO of Medgene, noted their company has existing vaccine manufacturing supply ready to deploy with capacity to support the U.S. dairy herd.